혈액암 (AML/ALL)

CGTBiologicstaleCARsgen Therapeutics Co., Ltd.Phase 1

Experimental: CAR-T cells Infusion (Experimental: CAR-T cells Infusion)

Multiple Myeloma; Primary Plasma Cell Leukemia · Multiple Myeloma

#MultipleMyeloma#CGT#Phase1#세포유전치료#CAR-T+3

AntibodystaleBiogenPhase 2

FCR + Lumiliximab (FCR + Lumiliximab)

Chronic Lymphocytic Leukemia · Chronic Lymphocytic Leukemia

#ChronicLymphocyticLeukemia#Antibody#Phase2#항체#면역항체+2

임상시험 1상태 DISCONTINUED

CGTBiologicstaleFred Hutchinson Cancer CenterPhase 1

FOLR1 CAR T-cells (FOLR1 CAR T-cells)

Recurrent Childhood Acute Myeloid Leukemia; Refractory Childhood Acute Myeloid Leukemia · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+4

효능 ORR 0%임상시험 1상태 RECRUITING

CGTBiologicstaleFate TherapeuticsPhase 1

Allogenic CAR NK cells with BCMA expression (FT576, FT576 (Allogenic CAR NK cells with BCMA expression))

Multiple Myeloma; Myeloma · BCMA

#BCMA#CGT#Phase1#세포유전치료#CAR-T+4

임상시험 1상태 ACTIVE

Flotetuzumab 10 ng/kg/day, 4 days on and 3 days off (Flotetuzumab 10 ng/kg/day, 4 days on and 3 days off)

AML · AML

Flotetuzumab 100 ng/kg/day, 4 days on and 3 days off (Flotetuzumab 100 ng/kg/day, 4 days on and 3 days off)

AML · AML

Flotetuzumab 3 ng/kg/day, 4 days on and 3 days off (Flotetuzumab 3 ng/kg/day, 4 days on and 3 days off)

AML · AML

Flotetuzumab 30 ng/kg/day, 4 days on and 3 days off (Flotetuzumab 30 ng/kg/day, 4 days on and 3 days off)

AML · AML

Flotetuzumab 300 ng/kg/day, 4 days on 3 days off, after one-step lead-in dose (Flotetuzumab 300 ng/kg/day, 4 days on 3 days off, after one-step lead-in dose)

AML · AML

Flotetuzumab 300 ng/kg/day, continuous infusion, after multi-step lead-in dose (Flotetuzumab 300 ng/kg/day, continuous infusion, after multi-step lead-in dose)

AML · AML

Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after one-step lead-in dose (Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after one-step lead-in dose)

AML · AML

Flotetuzumab 500 ng/kg/day, continuous infusion, after multi-step lead-in dose (Flotetuzumab 500 ng/kg/day, continuous infusion, after multi-step lead-in dose)

AML · AML

Flotetuzumab 700 ng/kg/day, 4 days on 3 days off, after multi-step lead-in dose (Flotetuzumab 700 ng/kg/day, 4 days on 3 days off, after multi-step lead-in dose)

AML · AML

Flotetuzumab 700 ng/kg/day, continuous infusion, after multi-step lead-in dose (Flotetuzumab 700 ng/kg/day, continuous infusion, after multi-step lead-in dose)

AML · AML

CGTBiologicstaleBenjamin TomlinsonPhase 1

Fully human anti CD19 CAR-T Cell Dose (Fully human anti CD19 CAR-T Cell Dose)

Non Hodgkin Lymphoma; Acute Lymphoblastic Leukemia · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+4

AntibodystaleRochePhase 2

Furmonertinib/Pemetrexed/Carboplatin/Bevacizumab (Furmonertinib/Pemetrexed/Carboplatin/Bevacizumab)

Non-small Cell Lung Cancer · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#Antibody#Phase2#항체#면역항체+2

ADCBiologicstalePfizerPreclinical

GO (Gemtuzumab Ozogamicin, Gemtuzumab Ozogamicin (GO))

Leukemia, Myeloid, Acute · Leukemia, Myeloid, Acute

#LeukemiaMyeloidAcute#ADC#Preclinical#항체약물접합체#antibody-drug-conjugate+4

임상시험 1상태 ACTIVE

CGTBiologicstaleWugen, Inc.Preclinical

Genetic: WU-CART-007 (Genetic: WU-CART-007)

T-cell Acute Lymphoblastic Leukemia; T-cell Lymphoblastic Lymphoma · T-cell Acute Lymphoblastic Leukemia

#T-cellAcuteLymphoblasticLeukemia#CGT#Preclinical#세포유전치료#CAR-T+3

임상시험 1상태 ACTIVE

CGTBiologicstaleFate TherapeuticsPreclinical

Genetically engineered NK cells (Genetically engineered NK cells)

Hematological Malignancy · Hematological Malignancy

#HematologicalMalignancy#CGT#Preclinical#세포유전치료#CAR-T+2